Study wrapper · #909
Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study.
Galasso M, Verde L, Patrone R, et al. Journal of translational medicine. 2026.
DOI: 10.1186/s12967-026-08558-4PubMed: 42464302
Editor's note
Tirzepatide is the direct subject, and the reported improvement in estimated GFR is an interesting signal tied largely to weight loss. However, the sample is very small, uncontrolled, and only three months long, so the findings are preliminary. Kidney function was estimated, not directly measured.
Plain-language abstract
In a small real-world study of 36 adults with obesity, three months of tirzepatide was associated with improved estimated kidney function alongside weight loss and better metabolic and inflammatory markers.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Mixed
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillarsn=——2026